VIVEK SUBBIAH to Small Cell Lung Carcinoma
This is a "connection" page, showing publications VIVEK SUBBIAH has written about Small Cell Lung Carcinoma.
Connection Strength
2.530
-
Lurbinectedin in patients with small cell lung cancer with chemotherapy-free interval =30 days and without central nervous metastases. Lung Cancer. 2024 02; 188:107448.
Score: 0.668
-
Pooled Safety Analysis of Single-Agent Lurbinectedin in Patients With Advanced Solid Tumours. Eur J Cancer. 2023 10; 192:113259.
Score: 0.649
-
Antitumor activity of lurbinectedin in second-line small cell lung cancer patients who are candidates for re-challenge with the first-line treatment. Lung Cancer. 2020 12; 150:90-96.
Score: 0.535
-
Lurbinectedin as second-line treatment for patients with small-cell lung cancer: a single-arm, open-label, phase 2 basket trial. Lancet Oncol. 2020 05; 21(5):645-654.
Score: 0.515
-
Immune-checkpoint inhibition for resectable non-small-cell lung cancer - opportunities and challenges. Nat Rev Clin Oncol. 2023 10; 20(10):664-677.
Score: 0.162